NASDAQ:CCXI - Nasdaq - US16383L1061 - Common Stock - Currency: USD
51.99
+0.03 (+0.06%)
The current stock price of CCXI is 51.99 USD. In the past month the price increased by 0.37%. In the past year, price increased by 50.39%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
CHEMOCENTRYX INC
835 Industrial Road, Suite 600
San Carlos CALIFORNIA 94043 US
CEO: Thomas J. Schall
Employees: 178
Company Website: https://www.chemocentryx.com/
Phone: 16502102900.0
The current stock price of CCXI is 51.99 USD. The price increased by 0.06% in the last trading session.
The exchange symbol of CHEMOCENTRYX INC is CCXI and it is listed on the Nasdaq exchange.
CCXI stock is listed on the Nasdaq exchange.
13 analysts have analysed CCXI and the average price target is 53.04 USD. This implies a price increase of 2.02% is expected in the next year compared to the current price of 51.99. Check the CHEMOCENTRYX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CHEMOCENTRYX INC (CCXI) has a market capitalization of 3.71B USD. This makes CCXI a Mid Cap stock.
CHEMOCENTRYX INC (CCXI) currently has 178 employees.
CHEMOCENTRYX INC (CCXI) has a support level at 51.98 and a resistance level at 52. Check the full technical report for a detailed analysis of CCXI support and resistance levels.
The Revenue of CHEMOCENTRYX INC (CCXI) is expected to grow by 117.77% in the next year. Check the estimates tab for more information on the CCXI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CCXI does not pay a dividend.
CHEMOCENTRYX INC (CCXI) will report earnings on 2022-11-08, after the market close.
CHEMOCENTRYX INC (CCXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
ChartMill assigns a technical rating of 8 / 10 to CCXI. When comparing the yearly performance of all stocks, CCXI is one of the better performing stocks in the market, outperforming 99.5% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to CCXI. CCXI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CCXI reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -6.78% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -357.01% | ||
ROA | -31.74% | ||
ROE | N/A | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 52% to CCXI. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.69% and a revenue growth 117.77% for CCXI